文献速递重症综合管理与镇静镇痛

重症监护病房获得性衰弱的血液炎症、神经肌肉和神经血管生物标志物谱纵向评估:一项前瞻性单中心队列研究

Longitudinal Assessment of Blood-Based Inflammatory, Neuromuscular, and Neurovascular Biomarker Profiles in Intensive Care Unit-Acquired Weakness: A Prospective Single-Center Cohort Study.
PubMed 文献 · Neurocrit Care · 2024-07-09
一句话结论ICU患者血液炎症、神经肌肉和神经血管生物标志物普遍升高,但均不能区分有无ICU获得性衰弱或危重病性神经肌病。

该前瞻性单中心队列研究纳入38例ICU患者(入ICU前5天内连续3天SOFA评分≥8)和10名健康对照,在第3、10、17天检测18种血液生物标志物,第10天以MRC肌力总评分<48定义ICUAW、以神经电图异常定义CINM。结果显示危重患者生物标志物较健康对照显著升高,并与疾病严重程度和3个月结局参数相关,但无论采用何种分类,均无生物标志物能区分有无神经肌肉损伤的患者。结论认为血液生物标志物在ICU患者中普遍升高,但不能识别ICUAW或CINM患者。

要点

  • 危重患者血液炎症、神经肌肉和神经血管生物标志物较健康对照显著升高,并与疾病严重程度和3个月结局参数相关。
  • 无论采用ICUAW还是CINM分类,18种生物标志物均不能区分有无神经肌肉损伤的患者。
  • ICUAW定义为第10天MRC肌力总评分<48,CINM定义为第10天神经电图异常。
  • 研究纳入38例ICU患者(ICUAW 18例有/20例无;CINM 18例有/17例无)和10名健康对照。
  • 结论:血液生物标志物不能识别ICUAW或CINM患者。

适用人群与场景

  • 入住ICU且前5天内连续3天序贯器官衰竭评估评分≥8的危重患者,以及健康对照。

诊断标准与关键阈值

  • ICUAW定义:第10天医学研究委员会肌力总评分(MRCSS)<48。
  • CINM定义:第10天神经电图(ENG)出现病理改变。

研究设计与关键结果

  • 研究类型:前瞻性单中心队列研究;纳入2016年10月至2018年12月间38例危重患者(ICUAW 18例有/20例无;CINM 18例有/17例无)和10名健康志愿者。
  • 于第3、10、17天采血定量分析18种生物标志物(白细胞计数、C反应蛋白、降钙素原、C端集聚蛋白片段、脂肪酸结合蛋白3、生长分化因子15、多配体蛋白聚糖1、肌钙蛋白I、干扰素-γ、肿瘤坏死因子-α、白细胞介素-1α、白细胞介素-1β、白细胞介素-4、白细胞介素-6、白细胞介素-8、白细胞介素-10、白细胞介素-13、单核细胞趋化蛋白1)。
  • 危重患者生物标志物较健康对照显著升高,并与疾病严重程度和3个月结局参数相关。
  • 无论采用何种分类,均无生物标志物能区分有无神经肌肉损伤的患者。

证据类型、等级与局限

  • 证据类型:前瞻性单中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论认为血液生物标志物在ICU患者中普遍升高,但不能识别ICUAW或CINM患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The diagnosis of intensive care unit (ICU)-acquired weakness (ICUAW) and critical illness neuromyopathy (CINM) is frequently hampered in the clinical routine. We evaluated a novel panel of blood-based inflammatory, neuromuscular, and neurovascular biomarkers as an alternative diagnostic approach for ICUAW and CINM.

METHODS: Patients admitted to the ICU with a Sequential Organ Failure Assessment score of ≥ 8 on 3 consecutive days within the first 5 days as well as healthy controls were enrolled. The Medical Research Council Sum Score (MRCSS) was calculated, and motor and sensory electroneurography (ENG) for assessment of peripheral nerve function were performed at days 3 and 10. ICUAW was defined by an MRCSS < 48 and CINM by pathological ENG alterations, both at day 10. Blood samples were taken at days 3, 10, and 17 for quantitative analysis of 18 different biomarkers (white blood cell count, C-reactive protein, procalcitonin, C-terminal agrin filament, fatty-acid-binding protein 3, growth and differentiation factor 15, syndecan 1, troponin I, interferon-γ, tumor necrosis factor-α, interleukin-1α [IL-1α], IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, and monocyte chemoattractant protein 1). Results of the biomarker analysis were categorized according to the ICUAW and CINM status. Clinical outcome was assessed after 3 months.

RESULTS: Between October 2016 and December 2018, 38 critically ill patients, grouped into ICUAW (18 with and 20 without) and CINM (18 with and 17 without), as well as ten healthy volunteers were included. Biomarkers were significantly elevated in critically ill patients compared to healthy controls and correlated with disease severity and 3-month outcome parameters. However, none of the biomarkers enabled discrimination of patients with and without neuromuscular impairment, irrespective of applied classification.

CONCLUSIONS: Blood-based biomarkers are generally elevated in ICU patients but do not identify patients with ICUAW or CINM.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02706314.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Klawitter F, Laukien F, Fischer DC, et al. Longitudinal Assessment of Blood-Based Inflammatory, Neuromuscular, and Neurovascular Biomarker Profiles in Intensive Care Unit-Acquired Weakness: A Prospective Single-Center Cohort Study. Neurocrit Care. 2024. PMID: 38982001. doi:10.1007/s12028-024-02050-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。